GE HealthCare Technologies is in talks to acquire radiopharmaceutical developer Sofie Biosciences for approximately $1 billion. The deal, which could be announced as soon as mid-September 2026, aims to bolster GE HealthCare's diagnostics division. Since its January 2023 spin-off from General Electric, GE HealthCare's stock has risen just 12%, trailing sister spin-offs GE Vernova and GE Aerospace. The company is also conducting a strategic review of its patient care solutions division.
Sofie Biosciences acquisition talks
- ▪The potential acquisition of Sofie Biosciences would mark the second major acquisition for GE HealthCare Technologies since its spin-off from General Electric
- ▪GE HealthCare Technologies is in talks to acquire Sofie Biosciences, a private equity-backed radiopharmaceutical developer, for approximately $1 billion, according to reports on September 13, 2026
- ▪Sofie Biosciences is largely owned by its founders, management, and private equity group Trilantic, which acquired a 25.8% stake in 2024 that valued the business at up to $550 million
- ▪The potential acquisition of Sofie Biosciences by GE HealthCare Technologies could be announced as soon as the week of September 14, 2026, provided there are no last-minute snags
Radiopharmaceutical cancer diagnostics
- ▪The acquisition of Sofie Biosciences is intended to bolster GE HealthCare Technologies' pharmaceutical diagnostics division, which supplies agents and chemicals used in medical scans
- ▪Sofie Biosciences, based in Dulles, Virginia, specializes in radioactive chemicals and is developing radioisotopes for use in PET scans to detect gastro-oesophageal and pancreatic cancers
GE HealthCare post-split performance
- ▪GE HealthCare Technologies spun off from General Electric in January 2023, followed by the spin-off of power company GE Vernova in April 2024
- ▪As of September 13, 2026, GE HealthCare Technologies' shares have risen 12% since its opening trading day, giving it a market value of $28.8 billion
- ▪Since the General Electric split, GE Vernova's market capitalization has increased sevenfold to $254 billion, while GE Aerospace's shares have more than doubled
Strategic business review
- ▪GE HealthCare Technologies announced a comprehensive review of strategic options for its patient care solutions division in July 2026
- ▪The July 2026 strategic review of the patient care solutions division is aimed at boosting performance by refocusing GE HealthCare Technologies on its core operations
Trian Fund stake increase
- ▪Trian Fund Management played an instrumental role in the three-way corporate break-up of General Electric
- ▪Billionaire investor Nelson Peltz's Trian Fund Management boosted its stake in GE HealthCare Technologies to nearly $200 million, as disclosed in a July 2026 regulatory filing
Story comments
Loading comments…